Search Results
Article Topics
Your search for all items matches 20289 pages
Showing 51 - 100Meta-analysis of Chemotherapy and Hormonal Treatments for Postmenopausal Women With Metastatic Breast Cancer
In a systematic review and network meta-analysis reported in The Lancet Oncology, Giuliano et al found that progression-free survival in postmenopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer was improved with first- or second-line CDK4/6 inhibitors plus...
Chef Uses Flavor to Fuel Her Mother’s Appetite During Cancer Treatment
The battle against cancer is typically waged by the surgeon and oncologist, but a Lexington, Kentucky–based, award-winning restaurateur and chef discovered her role as a foot soldier when she applied her culinary skills to deal with the debilitating side effects of her mother’s lung cancer...
FDA Pipeline: Breakthrough Therapy Designation in Lung Cancer, Orphan Drug Designations in Myeloma and Soft-Tissue Sarcoma
Recently, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to tepotinib for metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations, and Orphan Drug designations to novel chimeric antigen receptor T-cell therapies in both multiple myeloma ...
WCLC 2019: Video-Assisted Thoracic Surgery vs Open Surgery in Lung Cancer
Video-assisted thoracic surgery was associated with lower in-hospital complications and a shorter length of stay compared with open surgery among British patients who were diagnosed with early-stage lung cancer, according to research presented by Lim et al at the International Association for the...
WCLC 2019: Selpercatinib in RET Fusion–Positive NSCLC
Patients with RET fusion–positive non–small cell lung cancer (NSCLC) comprise up to 2% of all NSCLC cases, but there are no targeted therapies currently approved for patients with this form of lung cancer. Selpercatinib (also known as LOXO-292) is an oral and highly selective investigational drug...
WCLC 2019: KEYNOTE-024 Survival Update Shows Benefit With Pembrolizumab vs Chemotherapy in Advanced NSCLC
First-line pembrolizumab monotherapy provides durable long-term overall survival benefit compared to chemotherapy in patients with advanced non–small cell lung cancer (NSCLC), according to data from the KEYNOTE-024 trial presented by Martin Reck, MD, PhD, at the International Association for the...
Liquid Biopsy to Determine Patient Response to Immune Checkpoint Blockade
Although studies have demonstrated that microsatellite instability (MSI) and high tumor mutational burden (TMB) are promising pan-tumor biomarkers for identifying patients for treatment with immune checkpoint blockade, obtaining tissue from unresectable or metastatic solid tumors for genetic...
Neoadjuvant Cisplatin/Gemcitabine Followed by Standard Chemoradiation in Locally Advanced Cervical Cancer
In a Brazilian single-center phase II trial reported in the Journal of Clinical Oncology, da Costa et al found that neoadjuvant cisplatin/gemcitabine followed by standard chemoradiation therapy with cisplatin did not improve outcomes vs chemoradiation therapy alone in locally advanced cervical...
WCLC 2019: Declaration From IASLC on Tobacco Cessation After Cancer Diagnosis
The International Association for the Study of Lung Cancer (IASLC) used the platform of the 2019 World Conference on Lung Cancer (WCLC) to call attention to the importance of tobacco cessation after cancer diagnosis and urged all physicians to screen patients with cancer for tobacco use and...
WCLC 2019: Final Overall Survival Results of IMpower131 Trial in Advanced Squamous NSCLC
Patients with stage IV squamous non–small cell lung cancer (NSCLC) with high programmed cell death ligand 1 (PD-L1) expression treated with atezolizumab and chemotherapy experienced longer overall survival rates than those treated with chemotherapy alone. The data from the IMpower131 trial were...
WCLC 2019: BioMILD Trial of Blood MicroRNA Plus Low-Dose CT to Reduce CT Repeats in Lung Cancer Screening
Researchers from Milan reported that using a blood microRNA assay accompanied by low-dose computed tomography (CT) screening is safe and effective in screening patients for lung cancer. The results were shared at the International Association for the Study of Lung Cancer (IASLC) 2019 World...
WCLC 2019: Autoantibody Diagnostic Test Followed by CT Imaging May Improve Diagnosis, Reduce Mortality in Lung Cancer
A combination of the EarlyCDT-Lung Test followed by computed tomography (CT) imaging in Scottish patients at risk for lung cancer resulted in a significant decrease in late-stage diagnosis of lung cancer and may decrease lung cancer–specific mortality, according to research presented at...
Quality of Life and Neurocognitive Function With Lomustine/Temozolomide for MGMT-Methylated Glioblastoma
In an analysis of the phase III CeTeG/NOA-09 trial reported in The Lancet Oncology, Weller et al found no clinically relevant differences in health-related quality of life or neurocognitive function in patients with newly diagnosed MGMT-methylated glioblastoma treated with lomustine/temozolomide vs ...
Flu Vaccine Effectiveness in Patients With Cancer
In a Canadian study reported in the Journal of Clinical Oncology, Blanchette et al found the influenza vaccine was effective among patient with cancer, with greater effectiveness in patients with solid tumors vs those with hematologic malignancies. Study Details The population-based study involved...
Michael Kenneth Keng, MD, on an ASCO Quality Training Program: 5-Year Review
Michael Kenneth Keng, MD, of the University of Virginia, gives a status update on this international program, and discusses future initiatives which include coaching mentorship and publishing articles on quality care (Abstract 7).
Manali I. Patel, MD, on Community Practices: Enhancing Delivery of Value-Based Cancer Care
Manali I. Patel, MD, of Stanford Cancer Center, discusses enhancing value for patients with cancer treated by community practitioners at the end of life by also utilizing trained lay health workers in a novel intervention that reduced the use of acute care and emergency department visits while...
Cary P. Gross, MD, on Creating and Implementing Clinical Pathways: Where is the Patient’s Voice?
Cary P. Gross, MD, of Yale School of Medicine, discusses the challenges of implementing pathways and guiding patient decision-making on treatment.
Joseph O. Jacobson, MD, on Suffering, Systems, and Safety: The Joseph V. Simone Award Lecture
Joseph O. Jacobson, MD, of Dana-Farber Cancer Institute, and this year’s recipient of the award for excellence in quality cancer care, discusses the need for quality improvement (QI) to encompass systems of care, the role of QI in preventing suffering, how poor quality affects patient safety, and...
Nadine Housri, MD, on Online Tumor Boards: A New Resource for Practicing Oncologists
Nadine Housri, MD, of the Yale School of Medicine, talks about a new paradigm in sharing knowledge from tumor board discussions at NCI-designated comprehensive cancer centers, with community oncologists on themednet.org. Currently, thoracic, breast, and GI cancers are included, with plans to expand ...
Matthew B. Schabath, PhD, on Addressing Cultural Barriers to Equality in Oncology Among Sexual and Gender Minorities
Matthew B. Schabath, PhD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the disparities in cancer care among members of the LGBTQ community and the need to collect more data in order to close that gap.
Angela M. Stover, PhD, on Patient-Reported Outcome Performance Measures for Oncology Practice
Angela M. Stover, PhD, of the University of North Carolina at Chapel Hill, discusses ASCO’s initiative to develop patient-based performance measures for assessing and managing symptoms. The measures have made substantial differences in reducing nausea, constipation, and insomnia (Abstract 173).
Lauren M. Hamel, PhD, on Race and Doctor-Patient Behavior
Lauren M. Hamel, PhD, of Wayne State University/Karmanos Cancer Institute, discusses her findings on the ways in which nonverbal behavior between doctors and patients of the same or different races can affect their relationship, quality of communication, and ultimately, perhaps outcomes as well...
Mallika Sharma, MPH, on Eliminating Prior Authorizations, Anxiety, Delay in Care, Higher Costs
Mallika Sharma, MPH, of Seattle Cancer Care Alliance, discusses her findings that, by doing away with the many prior authorization denials based on administrative errors, providers may offer higher-value care by eliminating unnecessary anxiety among patients, administrative burdens, and increased...
Grace C. Hillyer, EdD, MPH, on Enrolling Patients in Clinical Trials: Improving Clinician-Patient Communication
Grace C. Hillyer, EdD, MPH, of Columbia University Mailman School of Public Health, discusses the many barriers to enrolling patients in clinical trials, most notably different attitudes toward and perceptions about research studies among clinicians vs patients. Her findings point to the need for...
Elena Martinez, PhD, MPH, on Diversity in Precision Oncology
Elena Martinez, PhD, MPH, of Moores Cancer Center at the University of California, San Diego, discusses the challenges of ensuring diversity in precision oncology and potential solutions to address the challenges.
Oncology Communications Online: Pause and Think Before Hitting ‘Send’
The emergence of online technologies over the past few decades has fundamentally changed the way society communicates and shares information. This sea change has also had profound influence on the practice of medicine, from real-time information-sharing among colleagues, to having instant access...
Ryan Huey, MD, on the Financial Toxicity of Early-Phase Clinical Trials
Ryan Huey, MD, of The University of Texas MD Anderson Cancer Center, discusses his findings that showed the large financial burden on lower-income patients enrolled in phase I trials (Abstract 8).
Cristina Merkhofer, MD, MHS, on NSCLC: Survival Impact of Taking Part in a Clinical Trial
Cristina Merkhofer, MD, MHS, of Fred Hutchinson Cancer Research Center, discusses study results showing that for patients with metastatic non–small cell lung cancer at her institution, enrolling in a therapeutic drug clinical trial was associated with a 47% lower risk of death, compared with not...
Bernardo H.L. Goulart, MD, on Stage IV NSCLC: High Drug Costs May Affect Survival
Bernardo H. L. Goulart, MD, of Seattle Cancer Care Alliance, discusses his findings that high out-of-pocket costs for oral tyrosine kinase inhibitors may lower survival rates, shorten the duration of therapy, and reduce the number of prescriptions for patients with metastatic EGFR- or ALK-positive...
WCLC 2019: Screening Efficacy of PLCOm2012 vs USPSTF Criteria
Researchers reported that a prospective trial comparing two screening methods for patients at risk of developing lung cancer found that a model used by Canadian, Australian, and European public health organizations detected more cancers than the screening model used by the United States Preventive...
Pamiparib Plus Tislelizumab in Advanced Solid Tumors
In an Australian phase Ia/b trial reported in The Lancet Oncology, Friedlander et al found evidence of activity of the combination of the poly (ADP-ribose) polymerase inhibitor pamiparib and the programmed cell death protein 1 inhibitor tislelizumab in patients with previously treated advanced...
T-DM1 Plus Neratinib in Metastatic HER2-Positive Breast Cancer
In the phase Ib NSABP Foundation Trial FB-10 reported in the Journal of Clinical Oncology, Jame Abraham, MD, and colleagues found evidence of activity of the combination of ado-trastuzumab emtansine (T-DM1) plus neratinib in metastatic HER2-positive breast cancer and identified the dose of the...
Olaparib Monotherapy Improves Outcomes in BRCA-Mutated, Platinum-Sensitive Relapsed Ovarian Cancer
Compared with treatment with nonplatinum-based chemotherapy, monotherapy with the PARP (poly [ADP ribose] polymerase) inhibitor olaparib led to statistically significant and clinically relevant improvements in overall response rate and progression-free survival in women with germline...
WCLC 2019: Survey Findings on Evidence-Based Guidelines for Molecular Testing in Lung Cancer
One-third of those who responded to a survey reported they are unaware of evidence-based guidelines that support the use of molecular testing in lung cancer, according to results from the International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung...
2019 Lasker Awards for Basic and Clinical Medical Research and Public Service Announced
On September 10, The Lasker Foundation announced the winners of its 2019 Lasker Awards: Max D. Cooper, MD, of Emory University, and Jacques Miller, AC, FRS, FAA, of the Walter and Eliza Hall Institute of Medical Research, will receive the Albert Lasker Basic Medical Research Award; H. Michael...
WCLC 2019: CASPIAN Trial Finds Addition of Durvalumab to Chemotherapy Improves Overall Survival in Patients With Extensive-Stage SCLC
The addition of durvalumab to chemotherapy improved overall survival in patients with extensive-stage small cell lung cancer (SCLC), according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) (Abstract PL02.11)....
WCLC 2019: Pooled Analysis of CheckMate 017 and 057: 5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC
Pooled data on two clinical trials demonstrated patients with previously treated non–small cell lung cancer (NSCLC) treated with nivolumab had a greater than fivefold increase in 5-year overall survival rate compared to treatment with the chemotherapy docetaxel. Scott Gettinger, MD, of Yale...
Erratum
In the August 10, 2019, issue of The ASCO Post, a photo on page 39, in an article about the National Comprehensive Cancer Network (NCCN) Policy Summit, was incorrectly identified as Terrell Johnson, MPA, an NCCN Policy and Advocacy Fellow. We regret the error and apologize to Mr. Johnson for the...
FDA Proposes New Required Health Warnings With Images for Cigarette Packages and Advertisements
On August 15, the U.S. Food and Drug Administration (FDA) issued a proposed rule to require new health warnings on cigarette packages and in advertisements to promote greater public understanding of the negative health consequences of smoking. The proposed warnings, which feature photo-realistic...
USPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommended risk assessment and, if indicated, genetic counseling and testing for potentially harmful BRCA1/2 mutations in women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have...
Circulating Tumor DNA and Relapse in Early-Stage Breast Cancer
In a study reported in JAMA Oncology, Nicholas C. Turner, PhD, and colleagues found that detection of circulating tumor DNA (ctDNA) during follow-up after initial treatment for early breast cancer was associated with a high risk of relapse. Detection at diagnosis was also associated with poorer...
Combined Use of Identification Methods for Dense Breasts and Discussion of Supplemental Imaging
In a study reported in JAMA Internal Medicine, Karla Kerlikowske, MD, and colleagues found that the combined use of Breast Imaging Reporting and Data System (BI-RADS) breast density and Breast Cancer Surveillance Consortium (BCSC)-defined risk for breast cancer may be an effective way of...
Combination CDK4/6 and EGFR Inhibition in Platinum- and Cetuximab-Resistant HPV-Unrelated Head and Neck Cancer
In a phase II study reported in The Lancet Oncology, Douglas Adkins, MD, and colleagues found that the combination of the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib and the EGFR inhibitor cetuximab showed activity in patients with either platinum- or cetuximab-resistant human...
HIV-Positive Older Adults With Cancer and Worsened Disease Outcomes
In a study reported in JAMA Oncology, Anna E. Coghill, PhD, MPH, and colleagues found that outcomes are often worse among human immunodeficiency virus (HIV)-positive patients aged 65 years or older with cancer vs HIV-negative patients with cancer, after adjustment for first courses of treatment....
Donald A.B. Lindberg, MD, Pathologist, Former Director of the National Library of Medicine, Dies at 85
The National Library of Medicine, located in Bethesda, Maryland, was started in 1836 as a small collection of medical books and journals in the office of the U.S. Army Surgeon General. In the ensuing years, the library grew to become the world’s largest and most prestigious biomedical library, with ...
John Hansen, MD, Transplant Expert Who Founded Volunteer Donor Registries, Dies at 76
Over the past few decades, our understanding of transplant immunology has moved from basic allograft rejection to the current molecular level that offers life-saving treatments for patients with cancer. The scientific elegance of this remarkable therapy’s arc from experimental to standard of care...
Having Cancer as a Teenager Derailed My Life Course
In 1994, I was a normal, active 15-year-old, who loved cars, sports, and rock music, especially songs from my favorite group, The Clash. In fact, it was while jubilantly dancing alone in my room to one of their tunes that I vomited into my hands, an early symptom of acute myeloid leukemia (AML). I...
A Vigorous Life Through the Prism of Impending Death
“Live while you’re living, friends,” writes Julie Yip-Williams in her memoir, The Unwinding of the Miracle: A Memoir of Life, Death, and Everything That Comes After. It was The New York Times bestseller when she died of stage IV colon cancer at the age of 42. She is the most recent of several...
Alpelisib for PIK3CA-Mutated Advanced Breast Cancer
On May 24, 2019, alpelisib was approved for use in combination with fulvestrant for postmenopausal women, and men, with hormone receptor–positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, as detected by a U.S. Food and Drug Administration (FDA)-approved test following...
Not for the Squeamish: Surgery in the 19th Century
Imagine undergoing major surgery in a grimy operating room without any form of antisepsis. That was the grim reality in the 1800s, when the ruling theory was that damage from “bad air” was responsible for infections in surgical wounds. Hospitals simply aired out the surgical wards at midday to...
